[1] |
XU X, WANG G, CHEN N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China[J]. J Am Soc Nephrol, 2016, 27(12):3739-3746.
PMID
|
[2] |
BECK L H Jr, BONEGIO R G, LAMBEAU G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21.
DOI
URL
|
[3] |
CHENG G, LIU J, GILBERT A, et al. Serum phospholipase A2 receptor antibodies and immunoglobulin G subtypes in adult idiopathic membranous nephropathy:clinical value assessment[J]. Clin Chim Acta, 2019, 490:135-141.
DOI
URL
|
[4] |
LI W, GUO Y, ZHANG Z, et al. Comparison of 2 anti-PLA2R immunoassays for the diagnosis of primary membranous nephropathy[J]. Lab Med, 2018, 49(4):316-322.
DOI
PMID
|
[5] |
BOBART S A, DE VRIESE A S, PAWAR A S, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies[J]. Kidney Int, 2019, 95(2):429-438.
DOI
URL
|
[6] |
MARCOULIDES K M, RAYKOV T. Evaluation of variance inflation factors in regression models using latent variable modeling methods[J]. Educ Psychol Meas, 2019, 79(5):874-882.
DOI
PMID
|
[7] |
HOFSTRA J M, DEBIEC H, SHORT C D, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 2012, 23(10):1735-1743.
PMID
|
[8] |
OH Y J, YANG S H, KIM D K, et al. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy[J]. PLoS One, 2013, 8(4):e62151.
DOI
URL
|
[9] |
RAO S J, SHEN Q, WANG H M, et al. The association of anti-PLA2R with clinical manifestations and outcomes in idiopathic membranous nephropathy:a meta-analysis[J]. Int Urol Nephrol, 2020, 52(11):2123-2133.
DOI
|
[10] |
王蒙, 王力宁, 刘楠, 等. 血清抗PLA2R抗体水平对特发性膜性肾病的诊断及预后评估[J]. 中国实用内科杂志, 2020, 40(2):153-157.
|
[11] |
BURBELO P D, JOSHI M, CHATURVEDI A, et al. Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy[J]. J Am Soc Nephrol, 2020, 31(1):208-217.
DOI
PMID
|
[12] |
RADICE A, TREZZI B, MAGGIORE U, et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor(PLA2R) for monitoring disease activity in idiopathic membranous nephropathy(IMN)[J]. Autoimmun Rev, 2016, 15(2):146-154.
DOI
URL
|
[13] |
SIOUTI E, ANDREAKOS E. The many facets of macrophages in rheumatoid arthritis[J]. Biochem Pharmacol, 2019, 165:152-169.
DOI
PMID
|
[14] |
MAGIL A B, WADSWORTH L D, LOEWEN M. Monocytes and human renal glomerular disease:a quantitative evaluation[J]. Lab Invest, 1981, 44(1):27-33.
DOI
URL
|
[15] |
TORRES Á, MUÑOZ K, NAHUELPÁN Y, et al. Intraglomerular monocyte/macrophage infiltration and macrophage-myofibroblast transition during diabetic nephropathy is regulated by the A2B adenosine receptor[J]. Cells, 2020, 9(4):1051.
DOI
URL
|
[16] |
FINSTERBUSCH M, HALL P, LI A, et al. Patrolling monocytes promote intravascular neutrophil activation and glomerular injury in the acutely inflamed glomerulus[J]. Proc Natl Acad Sci U S A, 2016, 113(35):E5172-E5181.
|
[17] |
ICHIRYU M S, MAGIL A B. Intraglomerular monocyte infiltration and immune deposits in diffuse lupus glomerulonephritis[J]. Am J Kidney Dis, 1999, 33(5):866-871.
PMID
|
[18] |
ALEXOPOULOS E, SERON D, HARTLEY R B, et al. Immune mechanisms in idiopathic membranous nephropathy:the role of the interstitial infiltrates[J]. Am J Kidney Dis, 1989, 13(5):404-412.
DOI
URL
|
[19] |
HOU J, ZHANG M, DING Y, et al. Circulating CD14+CD163+CD206+ M2 monocytes are increased in patients with early stage of idiopathic membranous nephropathy[J]. Mediators Inflamm, 2018, 2018:5270657.
|
[20] |
ANDERS H J, RYU M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis[J]. Kidney Int, 2011, 80(9):915-925.
DOI
URL
|
[21] |
KUROKI A, IYODA M, SHIBATA T, et al. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy[J]. Kidney Int, 2005, 68(1):302-310.
DOI
PMID
|